HomeCompareDNB vs JNJ

DNB vs JNJ: Dividend Comparison 2026

DNB yields 1.64% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.4K in total portfolio value· pulled ahead in Year 6
10 years
DNB
DNB
● Live price
1.64%
Share price
$9.15
Annual div
$0.15
5Y div CAGR
-10.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$55.20
Full DNB calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — DNB vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNBJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNB + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNB pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNB
Annual income on $10K today (after 15% tax)
$139.34/yr
After 10yr DRIP, annual income (after tax)
$46.92/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $3,990.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNB + JNJ for your $10,000?

DNB: 50%JNJ: 50%
100% JNJ50/50100% DNB
Portfolio after 10yr
$25.8K
Annual income
$2,402.54/yr
Blended yield
9.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DNB
Analyst Ratings
8
Buy
7
Hold
Consensus: Buy
Price Target
$19.17
+109.5% upside vs current
Range: $12.00 — $24.00
Altman Z
0.6
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNB buys
0
JNJ buys
0
No recent congressional trades found for DNB or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNBJNJ
Forward yield1.64%2.14%
Annual dividend / share$0.15$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-10.9%28%
Portfolio after 10y$21.1K$30.5K
Annual income after 10y$55.20$4,749.88
Total dividends collected$949.00$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$19.17$228.73

Year-by-year: DNB vs JNJ ($10,000, DRIP)

YearDNB PortfolioDNB Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,846$146.07$10,594$274.49+$252.00DNB
2$11,737$131.92$11,294$360.69+$443.00DNB
3$12,678$118.88$12,133$476.91+$545.00DNB
4$13,672$106.92$13,156$635.42+$516.00DNB
5$14,725$96.02$14,432$854.61+$293.00DNB
6← crossover$15,842$86.11$16,056$1,162.76$214.00JNJ
7$17,028$77.15$18,175$1,604.53$1.1KJNJ
8$18,289$69.05$21,009$2,252.68$2.7KJNJ
9$19,631$61.76$24,911$3,229.73$5.3KJNJ
10$21,060$55.20$30,458$4,749.88$9.4KJNJ

DNB vs JNJ: Complete Analysis 2026

DNBStock

Dun & Bradstreet Holdings, Inc. provides business decisioning data and analytics in North America and internationally. It offers finance and risk solutions, including D&B Finance Analytics, an online application that offers clients real time access to its information, comprehensive monitoring, and portfolio analysis; D&B Direct, an application programming interface (API) that delivers risk and financial data directly into enterprise applications for real-time credit decision making; D&B Small Business, a suite of powerful tools that allows SMBs to monitor and build their business credit file; D&B Enterprise Risk Assessment Manager, a solution for managing and automating credit decisioning and reporting; and InfoTorg, an online SaaS application. The company also provides risk and compliance solutions, such as D&B Supplier Risk Manager that provides insights to help certify, monitor, analyze, and mitigate risk across the supply chain; D&B Onboard to provide comprehensive insights into businesses to facilitate KYC/AML compliance, as well as to minimize financial, legal, and reputational risk exposure; and D&B Beneficial Ownership that offers risk intelligence on ultimate beneficial ownership. It offers sales and marketing solutions, including D&B Connect, a self-service data management platform; D&B Optimizer, an integrated data management solution; D&B Rev.Up ABX, an open and agnostic platform that aligns marketing and sales teams to deliver an optimal and coordinated buying; D&B Hoovers, a sales intelligence solution; D&B Audience Targeting, which helps clients to reach the right audiences with the right messages; D&B Visitor Intelligence that turns web visitors into leads; and D&B Direct, an API-enabled data management solution that delivers valuable customer insights into CRMs, marketing automation, and other marketing applications for on-demand business intelligence. The company was founded in 1841 and is headquartered in Jacksonville, Florida.

Full DNB Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DNB vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNB vs SCHDDNB vs JEPIDNB vs ODNB vs KODNB vs MAINDNB vs ABBVDNB vs MRKDNB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.